Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype

Immunotherapy with histamine dihydrochloride and low-dose interleukin-2 (HDC/IL-2) reduces the risk of relapse in the post-chemotherapy phase of acute myeloid leukemia (AML). Here we report the results of exploratory analyses of the clinical efficacy of HDC/IL-2 in AML with focus on the impact of ka...

Descripción completa

Detalles Bibliográficos
Autores principales: Nilsson, Malin S., Hallner, Alexander, Brune, Mats, Nilsson, Staffan, Thorén, Fredrik B., Martner, Anna, Hellstrand, Kristoffer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012093/
https://www.ncbi.nlm.nih.gov/pubmed/31242079
http://dx.doi.org/10.1080/21645515.2019.1636598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012093/
https://www.ncbi.nlm.nih.gov/pubmed/31242079
http://dx.doi.org/10.1080/21645515.2019.1636598

Ejemplares similares